Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 740.00 GBp
Change Today -15.50 / -2.05%
Volume 1.3M
BTG On Other Exchanges
As of 11:35 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

btg plc (BTG) Snapshot

758.00 GBp
Previous Close
755.50 GBp
Day High
758.00 GBp
Day Low
734.00 GBp
52 Week High
01/9/15 - 834.50 GBp
52 Week Low
05/16/14 - 508.50 GBp
Market Cap
Average Volume 10 Days
0.11 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for BTG PLC (BTG)

Related News

No related news articles were found.

btg plc (BTG) Related Businessweek News

No Related Businessweek News Found

btg plc (BTG) Details

BTG plc, a specialist healthcare company, develops and commercializes products targeting critical care, cancer, and varicose veins. It operates through three segments: Specialty Pharmaceuticals, Interventional Medicine, and Licensing & Biotechnology. The company markets and sells specialty pharmaceuticals, including CroFab, a treatment for patients bitten by North American pit vipers; DigiFab, a treatment for patients suffering toxicity associated with the use of the heart medicine digoxin; and Voraxaze, a treatment for toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It also offers a range of interventional oncology products comprising Bead Block, TheraSphere, LC Bead, and DC Bead used to treat patients with hypervascularized tumors; and EkoSonic Endovascular System for the treatment of patients with severe blood clots, and Varithena polidocanol injectable foam for the treatment for patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. The company’s products in late-stage development include TheraSphere in Phase 3 clinical trials in hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC); Beads in investigator-initiated/registration studies in HCC and 3rd line mCRC; and Uridine triacetate in development with Wellstat Therapeutic Corporation as a treatment for toxicity associated with the use of the chemotherapeutic 5-fluorouracil. The company’s licensing products comprise Zytiga, a treatment for patients with prostate cancer; Two-Part Hip Cup, a prosthetic hip joint replacement licensed to hip-replacement technology manufacturers; and Lemtrada, a treatment for patients with relapsing-remitting multiple sclerosis. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

860 Employees
Last Reported Date: 06/16/14
Founded in 1948

btg plc (BTG) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.0M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 657.0K GBP
Compensation as of Fiscal Year 2014.

btg plc (BTG) Key Developments

BTG plc Begins Sale of DC Bead® and Bead Block® Directly to Physicians

BTG plc began selling its drug-eluting bead and embolisation products, DC Bead® and Bead Block®, directly to customers in 11 European countries. DC Bead® and Bead Block®, developed and manufactured by BTG, both received CE Mark approval in Europe in 2003. These products were previously sold in Europe by the Terumo Corporation under a contract that expired on 31 March 2015. BTG will be selling directly to hospitals in Austria, Belgium, France, Germany, Ireland, Italy, Netherlands, Portugal, Switzerland, Spain, and the UK. Through the growth of its embolic bead products, the acquisitions of TheraSphere® and EKOS Corporation, the US approval of Varithena®, and the acquisition of interventional pulmonology company PneumRx earlier in 2014, BTG has become a leader in interventional medicine. Interventional medicine is a minimally invasive approach that relies on using medical imaging to deliver treatments precisely where they are needed in the body. This is a fast-growing area of medicine, driven by demand for better treatments and outcomes, advances in imaging techniques and product innovation. BTG is working with healthcare professionals across disciplines to realise the full potential of interventional medicine to treat patients.

BTG plc Revises Revenue Guidance for the Year Ending 31 March 2015

BTG plc revised revenue guidance for the year ending 31 March 2015. For the full year, revenue is now expected to be in the range £345 million-£360 million; previous guidance was £330 million to £345 million. The new guidance reflects the acquisition of PneumRx Inc, which completed on 7 January 2015, and a reversal of the adverse foreign exchange impact reported for the six months to 30 September 2014.

BTG plc, Board Meeting, Feb 05, 2015

BTG plc, Board Meeting, Feb 05, 2015. Agenda: To decide that in future the company will not publish interim management statements.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTG:LN 740.00 GBp -15.50

BTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Impax Laboratories Inc $46.99 USD +0.33
Merit Medical Systems Inc $20.85 USD +0.27
Pfizer Ltd/India 2,019 INR -26.75
RPX Corp $15.10 USD -0.015
Medicines Co/The $26.30 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation BTG Industry Range
Price/Earnings 65.2x
Price/Sales 7.8x
Price/Book 4.4x
Price/Cash Flow 40.9x
TEV/Sales 8.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at